- Home
- IHT vs CVKD Comparison
IHT vs CVKD Comparison
Compare IHT & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHT
- CVKD
- Stock Information
- Founded
- IHT 1971
- CVKD 2022
- Country
- IHT United States
- CVKD United States
- Employees
- IHT N/A
- CVKD N/A
- Industry
- IHT Investment Bankers/Brokers/Service
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- IHT Finance
- CVKD Health Care
- Exchange
- IHT Nasdaq
- CVKD Nasdaq
- Market Cap
- IHT 22.2M
- CVKD 34.2M
- IPO Year
- IHT N/A
- CVKD 2023
- Fundamental
- Price
- IHT $2.64
- CVKD $17.77
- Analyst Decision
- IHT
- CVKD Strong Buy
- Analyst Count
- IHT 0
- CVKD 1
- Target Price
- IHT N/A
- CVKD $32.00
- AVG Volume (30 Days)
- IHT 2.7K
- CVKD 44.3K
- Earning Date
- IHT 04-07-2025
- CVKD 05-08-2025
- Dividend Yield
- IHT 0.78%
- CVKD N/A
- EPS Growth
- IHT N/A
- CVKD N/A
- EPS
- IHT N/A
- CVKD N/A
- Revenue
- IHT $7,692,305.00
- CVKD N/A
- Revenue This Year
- IHT N/A
- CVKD N/A
- Revenue Next Year
- IHT N/A
- CVKD N/A
- P/E Ratio
- IHT N/A
- CVKD N/A
- Revenue Growth
- IHT 4.55
- CVKD N/A
- 52 Week Low
- IHT $1.25
- CVKD $5.40
- 52 Week High
- IHT $2.70
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- IHT 49.09
- CVKD 49.27
- Support Level
- IHT $2.53
- CVKD $14.64
- Resistance Level
- IHT $2.69
- CVKD $17.58
- Average True Range (ATR)
- IHT 0.07
- CVKD 1.86
- MACD
- IHT -0.01
- CVKD -0.29
- Stochastic Oscillator
- IHT 33.63
- CVKD 39.10
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.